Akcea initiates phase 2 study of AKCEA-APO(a)-L Rx in patients with high Lp(a)
Akcea announced initiation of a Phase 2b dose-ranging study of AKCEA-APO(a)-LRx in patients with hyperlipoproteinemia(a) and established cardiovascular disease. The goal is to determine the dose level and frequency for use of AKCEA-APO(a)-LRx in a planned Phase 3 outcome study. March 30, 2017